Arthur Mortha

BACKGROUND: Anti-granulocyte macrophage-colony stimulating factor autoantibodies (anti-GM-CSF) have been associated with development of Crohn’s disease (CD) and complications at time of diagnosis. There are limited data on anti-GM-CSF as a prognostic biomarker in CD…

Anti-granulocyte/macrophage-colony stimulating factor autoantibody (GM-CSF AuAB) has been identified before the onset of Crohn’s Disease (CD) and is associated with an increase in complicated disease. However, its connection to the gut microbiome, a key factor in CD progression, remains unclear…

Granulocyte Macrophage-Colony Stimulating Factor (GM-CSF) maintains mononuclear phagocytes (MNP) and supports intestinal immune homeostasis. Anti-GM-CSF autoantibodies (aGMAbs) are found in approx. 25% of all Crohn’s disease (CD) patients…